คู่มือโดยละเอียดเร็วๆ นี้
เรากำลังจัดทำคู่มือการศึกษาที่ครอบคลุมสำหรับ FIB-4 Score (Liver Fibrosis) กลับมาเร็วๆ นี้เพื่อดูคำอธิบายทีละขั้นตอน สูตร ตัวอย่างจริง และเคล็ดลับจากผู้เชี่ยวชาญ
The Fibrosis-4 Index (FIB-4) is a non-invasive, blood-based scoring tool used to estimate the degree of hepatic fibrosis in patients with chronic liver disease, most commonly chronic hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD/MASLD). Developed by Sterling and colleagues in 2006 using data from HIV/HCV co-infected patients enrolled in the APRICOT trial, it uses four routinely available variables: patient age, AST (aspartate aminotransferase), platelet count, and ALT (alanine aminotransferase). The resulting score correlates with liver biopsy-staged fibrosis and allows non-invasive categorisation of patients into those with no/minimal fibrosis (F0–F1), indeterminate fibrosis requiring further testing, and advanced fibrosis/cirrhosis (F3–F4). The principal clinical value of FIB-4 is its ability to identify patients who are unlikely to have advanced fibrosis and can therefore be spared from liver biopsy and more invasive investigations. A FIB-4 score below 1.30 has a negative predictive value of approximately 90% for excluding advanced fibrosis, while a score above 2.67 has a positive predictive value of approximately 80% for confirming advanced fibrosis. The indeterminate zone (1.30–2.67) often requires supplementary testing such as liver stiffness measurement by transient elastography (FibroScan). FIB-4 is endorsed by multiple international hepatology and gastroenterology societies and is increasingly used as a first-line population-level screening tool in primary care for early identification of advanced liver disease.
FIB-4 = (Age [years] × AST [U/L]) / (Platelet count [10^9/L] × sqrt(ALT [U/L])) Where each variable represents a specific measurable quantity in the finance and lending domain. Substitute known values and solve for the unknown. For multi-step calculations, evaluate inner expressions first, then combine results using the standard order of operations.
- 1Collect four routine laboratory and demographic values: patient age in years, serum AST (aspartate aminotransferase) in U/L, serum ALT (alanine aminotransferase) in U/L, and platelet count in 10^9/L (or ×10³/µL).
- 2Calculate the square root of the ALT value (√ALT). This accounts for the non-linear relationship between ALT and fibrosis stage.
- 3Multiply the platelet count (in 10^9/L) by the square root of ALT to form the denominator.
- 4Multiply age by AST to form the numerator — age amplifies the contribution of AST because fibrosis accumulates over time.
- 5Divide the numerator (Age × AST) by the denominator (Platelets × √ALT) to obtain the FIB-4 index.
- 6Apply the threshold interpretation: FIB-4 <1.30 = F0–F1 (advanced fibrosis unlikely, ~90% NPV); FIB-4 1.30–2.67 = indeterminate (refer for elastography); FIB-4 >2.67 = F3–F4 (advanced fibrosis likely, ~80% PPV).
- 7Note: age-adjusted cut-offs are recommended — for patients aged ≥65 years, the lower cut-off rises to 2.0 (to reduce false positives from age-related platelet decline and AST changes).
FIB-4 < 1.30 — advanced fibrosis (F3–F4) is unlikely; no biopsy needed
A young patient with only modestly elevated liver enzymes and a normal platelet count produces a low FIB-4 score, effectively ruling out advanced fibrosis and avoiding the need for invasive testing.
FIB-4 > 2.67 — advanced fibrosis likely; refer for FibroScan or biopsy
Despite appearing as a routine middle-aged patient, the combination of age, elevated AST relative to ALT, and mildly reduced platelets pushes the FIB-4 into the high-risk zone.
FIB-4 >> 2.67 — highly suggestive of cirrhosis (F4); refer to hepatologist
Thrombocytopenia (a consequence of portal hypertension and hypersplenism) combined with elevated AST and older age produces a very high FIB-4 score, consistent with established cirrhosis.
Standard cut-off: positive for advanced fibrosis. With age-adjusted cut-off ≥65: lower threshold 2.0 still exceeded — refer for further evaluation
Age-adjusted cut-offs (lower: 2.0, upper: 2.67 for ≥65 years) improve specificity in elderly patients. This score of 3.41 exceeds both thresholds, warranting hepatology referral.
Mortgage lenders and loan officers use Fibrosis4 Score to structure repayment schedules, compare fixed versus adjustable rate options, and calculate total borrowing costs for residential and commercial real estate transactions across different term lengths.
Personal finance advisors apply Fibrosis4 Score when counseling clients on debt reduction strategies, comparing the mathematical benefit of accelerated payments against alternative investment returns to determine the optimal allocation of surplus cash flow.
Credit unions and community banks rely on Fibrosis4 Score to generate accurate Truth in Lending disclosures, ensure regulatory compliance with TILA and RESPA requirements, and provide borrowers with standardized cost comparisons across competing loan products.
Corporate treasury departments use Fibrosis4 Score to model the cost of revolving credit facilities, term loans, and commercial paper programs, optimizing the company's capital structure and minimizing weighted average cost of debt financing.
Zero or negative interest rate
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in fibrosis4 score calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Balloon payment at maturity
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in fibrosis4 score calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Variable rate mid-term adjustment
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in fibrosis4 score calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Concurrent thrombocytopenia from non-hepatic causes
Patients with immune thrombocytopenia (ITP), chemotherapy-induced thrombocytopenia, or hypersplenism from non-hepatic causes will have falsely elevated FIB-4 due to low platelet counts. Clinical context and supplementary tests are needed before attributing a high score to liver fibrosis.
| FIB-4 Score | Fibrosis Stage | Clinical Action |
|---|---|---|
| < 1.30 (age <65) | F0–F1 — advanced fibrosis unlikely | Reassure; recheck in 1–2 years if risk factors persist |
| < 2.0 (age ≥65) | F0–F1 — advanced fibrosis unlikely | Age-adjusted low-risk threshold for elderly patients |
| 1.30–2.67 | Indeterminate | Perform liver stiffness measurement (FibroScan) or biopsy |
| > 2.67 | F3–F4 — advanced fibrosis/cirrhosis likely | Urgent hepatology referral; consider portal hypertension screening |
| NPV at <1.30 | ~90% | Strong evidence to exclude advanced fibrosis |
| PPV at >2.67 | ~80% | High probability of confirmed advanced fibrosis on biopsy |
What is the FIB-4 score used for?
Fibrosis4 Score is a specialized calculation tool designed to help users compute and analyze key metrics in the finance and lending domain. It takes specific numeric inputs — typically drawn from real-world data such as measurements, rates, or quantities — and applies a validated mathematical formula to produce actionable results. The tool is valuable because it eliminates manual calculation errors, provides instant feedback when exploring different scenarios, and serves as both a decision-support instrument for professionals and a learning aid for students studying the underlying principles.
What is the difference between FIB-4 and APRI?
Fibrosis4 Score is a specialized calculation tool designed to help users compute and analyze key metrics in the finance and lending domain. It takes specific numeric inputs — typically drawn from real-world data such as measurements, rates, or quantities — and applies a validated mathematical formula to produce actionable results. The tool is valuable because it eliminates manual calculation errors, provides instant feedback when exploring different scenarios, and serves as both a decision-support instrument for professionals and a learning aid for students studying the underlying principles.
Can FIB-4 replace liver biopsy?
In the context of Fibrosis4 Score, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Why does age matter in FIB-4?
In the context of Fibrosis4 Score, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Is FIB-4 validated in NAFLD?
In the context of Fibrosis4 Score, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
What are age-adjusted FIB-4 cut-offs?
In the context of Fibrosis4 Score, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Can FIB-4 be used to monitor treatment response?
Yes. Serial FIB-4 measurements can track changes in fibrosis over time, particularly in patients treated for hepatitis C (where successful cure often leads to FIB-4 improvement) or NAFLD (where weight loss and lifestyle changes can regress fibrosis). However, changes must be interpreted cautiously as the score can fluctuate with enzyme levels independent of fibrosis.
What conditions cause falsely elevated FIB-4?
In the context of Fibrosis4 Score, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
เคล็ดลับโปร
In patients with a FIB-4 in the indeterminate range (1.30–2.67), the next step is liver stiffness measurement by transient elastography (FibroScan). A two-step pathway (FIB-4 first, then FibroScan for indeterminate results) substantially reduces unnecessary biopsies compared to proceeding directly to biopsy from an abnormal FIB-4.
คุณรู้ไหม?
The FIB-4 index was originally published in 2006 as a byproduct of the APRICOT clinical trial for HIV/HCV co-infection, where researchers needed a simple tool to avoid performing biopsies in all trial participants. Its success in that niche population led to its adoption across all forms of chronic liver disease — one of medicine's more fortunate accidental discoveries.
เอกสารอ้างอิง
- ›Sterling RK et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006.
- ›EASL Clinical Practice Guidelines on Non-Invasive Tests for Evaluation of Liver Disease Severity. J Hepatol 2021.
- ›Vallet-Pichard A et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Hepatology 2007.
- ›AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
- ›MDCalc — FIB-4 Index for Liver Fibrosis